This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
by Zacks Equity Research
Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.
Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of +25.32% and +4.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
by Zacks Equity Research
Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
by Zacks Equity Research
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of Regeneron (REGN) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised
by Zacks Equity Research
Roche's Q3 sales climbed 6% to CHF 14.9B, powered by surging demand for Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus.
Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
by Kanishka Das
Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)
by Zacks Equity Research
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss
by Zacks Equity Research
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo
by Zacks Equity Research
REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
by Zacks Equity Research
Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
by Zacks Equity Research
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
by Zacks Equity Research
Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
by Zacks Equity Research
Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?
by Zacks Equity Research
Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
NKTR Shares Surge 38.2% in a Week: Here's What You Should Know
by Zacks Equity Research
Nektar shares surge 38.2% on investor optimism on rezpeg's potential in atopic dermatitis after upbeat mid-stage study results.
RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress
by Zacks Equity Research
Roche posts strong new data for Vabysmo in eye disease, with extended dosing and vision gains driving growth.
SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study
by Zacks Equity Research
Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.
Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline
by Kanishka Das
Merck advances growth with phase III pipeline backed by positive data for its potential first oral PCSK9 inhibitor.
Immuneering Stock Rises 21.7% on Supply Agreement With LLY
by Zacks Equity Research
IMRX jumps 21.7% after striking a supply deal with Eli Lilly to test atebimetinib with the latter's olomorasib in non-small cell lung cancer.
The Zacks Analyst Blog Highlights Health Care Select Sector SPDR, SPDR S&P 500 ETF Trust, UnitedHealth, Regeneron, CVS Health and Novo Nordisk
by Zacks Equity Research
Healthcare stocks trade at a 30-year discount, with XLV showing signs of rebound as Buffett and hedge funds boost exposure.